
GSK Secures FDA Approval for Jideytro in Lung Cancer Treatment
The US Food and Drug Administration has approved Jideytro, a targeted therapy for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer who have previously undergone treatment with a kinase inhibitor. This milestone marks GSK’s entry into the lung cancer market following its recent acquisition of Nuvalent, Inc.
























